Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

SOP for Preparation of Multilamellar Vesicles (MLVs)

Posted on By

SOP for Preparation of Multilamellar Vesicles (MLVs)

Preparation of Multilamellar Vesicles (MLVs)

1) Purpose

This SOP outlines the procedure for the preparation of multilamellar vesicles (MLVs) in liposome formulations. MLVs consist of multiple lipid bilayers and are commonly used in drug delivery systems, as they can encapsulate both hydrophilic and lipophilic drugs. This method is suitable for creating larger vesicles that provide controlled release of encapsulated materials.

2) Scope

This SOP applies to all personnel involved in the preparation of multilamellar vesicles (MLVs) in a laboratory or production setting. It includes lipid preparation, hydration, and analysis of the resulting vesicles.

3) Responsibilities

  • Operators: Responsible for preparing MLVs according to the procedures described in this SOP and documenting all steps in the batch records.
  • QA Team: Responsible for reviewing the batch records and ensuring that the preparation of MLVs is compliant with the SOP and regulatory guidelines.
  • QC Team: Responsible for performing quality control tests to confirm the size, encapsulation efficiency, and stability of the MLVs.
See also  SOP for Optimization of Droplet Size in Emulsion Formulations

4) Procedure

4.1 Equipment Setup

Ensure that all equipment is calibrated and ready for use before beginning the preparation of MLVs.

4.1.1 Required Equipment

  • Rotary evaporator
  • Magnetic stirrer
  • Temperature-controlled water bath
  • pH meter
  • Particle size analyzer (DLS)

4.1.2 Equipment Calibration

  • 4.1.2.1 Calibrate the rotary evaporator, ensuring that the temperature and vacuum settings are accurate for solvent removal.
  • 4.1.2.2 Verify the calibration of the pH meter using standard buffer solutions (pH 4.0, 7.0, and 10.0).

4.2 Lipid Preparation

The lipid components of the MLVs must be dissolved and prepared for hydration to form multilamellar structures. Follow these steps for lipid preparation:

  • 4.2.1 Weigh the required amount of lipids (e.g., phospholipids and cholesterol) according to the formulation protocol. Record the weights in the Batch Manufacturing Record (BMR).
  • 4.2.2 Dissolve the lipids in an organic solvent, such as chloroform or methanol, in a round-bottom flask.
  • 4.2.3 Evaporate the solvent using a rotary evaporator to form a thin lipid film on the inner surface of the flask.
  • 4.2.4 Dry the lipid film under vacuum for 30 minutes to remove any remaining solvent.
See also  SOP for Formulating Self-Emulsifying Drug Delivery Systems (SEDDS)

4.3 Hydration of Lipid Film

The lipid film is hydrated with an aqueous phase to form multilamellar vesicles (MLVs). The following steps outline the hydration process:

  • 4.3.1 Add the pre-warmed aqueous phase (e.g., buffer or drug solution) to the flask containing the dried lipid film.
  • 4.3.2 Stir the suspension using a magnetic stirrer or vortex for 30 minutes to allow the lipid film to hydrate and form MLVs.
  • 4.3.3 Ensure that the temperature of the water bath is set above the lipid phase transition temperature (typically 37°C) to facilitate proper hydration.
  • 4.3.4 Adjust the pH of the aqueous phase as needed using the pH meter to maintain the stability of the MLVs and the encapsulated drug.

4.4 Quality Control of MLVs

Once the MLVs are prepared, perform the following quality control tests to assess their size, stability, and encapsulation efficiency:

  • 4.4.1 Measure the particle size of the MLVs using dynamic light scattering (DLS) or another particle sizing method.
  • 4.4.2 Test the encapsulation efficiency by analyzing the concentration of the drug or active ingredient encapsulated in the MLVs.
  • 4.4.3 Evaluate the stability of the MLVs by storing them at the required conditions and monitoring their size and morphology over time.
See also  SOP for Microbiological Stability Testing of Emulsions

5) Abbreviations, if any

  • MLV: Multilamellar Vesicle
  • DLS: Dynamic Light Scattering
  • QA: Quality Assurance
  • QC: Quality Control

6) Documents, if any

  • Batch Manufacturing Record (BMR)
  • Particle Size Analysis Report
  • pH Calibration Log

7) References, if any

  • FDA Guidelines for Liposomal Drug Products
  • ICH Q7: Good Manufacturing Practice Guide

8) SOP Version

Version 1.0

Annexure

Annexure 1: Batch Manufacturing Record Template

Batch No. Lipid Type Weight Aqueous Phase Hydration Time Temperature Operator Initials QA Signature
Batch Number Lipid Name Weight in grams Buffer/Drug Solution Minutes Temperature in °C Operator Name QA Name
               
Liposome and Emulsion Formulations Tags:Antioxidants in emulsions, API incorporation in emulsions, API incorporation in liposomes, Chemical stability testing liposomes, Cosmetic emulsion formulation, Emulsion droplet size analysis, Emulsion formulation SOP, Emulsion microbiological stability, Emulsion stability testing, Freeze-thaw stability testing, Heat-sensitive liposomes, High-shear mixing emulsions, Liposomal drug delivery SOP, Liposomal vaccines SOP, Liposome formulation SOP, Liposome particle size analysis, Liposome preparation procedure, Liposome size distribution, Liposome stability testing, Nanoemulsion SOP, Parenteral emulsion preparation, pH-responsive emulsions, Physical stability liposomes, Self-emulsifying drug delivery systems (SEDDS), Thin-film hydration liposomes

Post navigation

Previous Post: SOP for Preparation of Nanocrystals for Drug Delivery
Next Post: SOP for Incorporation of Controlled Release Agents in Lyophilized Products

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version